Azitra adjusted the protocol of its topical ATR-04-484 Phase 1/2 study to include patients treating rash caused by KRAS and MEK inhibitors, widening the potential patient pool beyond those on EGFR inhibitors.
Azitra adjusted the protocol of its topical ATR-04-484 Phase 1/2 study to include patients treating rash caused by KRAS and MEK inhibitors, widening the potential patient pool beyond those on EGFR inhibitors.